Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Targeting the PIM Kinase Family.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PIM3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Active Kinase (WT) | PIM3 Full Length / Kinase Domain; high purity (>95%), theoretical MW verified, sequence verified, suitable for ATP-competitive binding. | View PIM3 Products |
| Resistance Mutant (T85M) | PIM3 T85M Gatekeeper Mutant Protein; sequence verified by mass spec, for resistance profiling and selectivity studies. | View PIM3 Products |
| Selectivity Panel | PIM1 & PIM2 Kinase Proteins; for off-target screening (high homology family); HEK293 or E. coli expressed. | View PIM1 Products |
| Gene Delivery | PIM3 Lentivirus (Premade Particles); for stable cell line generation; endotoxin controlled. | View PIM3 Products |
| Validator | PIM3 siRNA Set; for specific knockdown validation in cellular assays. | View PIM3 Products |
| Pathway Partner | c-MYC (MYC); downstream substrate validation (PIM3 stabilizes MYC). | View MYC Products |
| Benchmark Antibody | Anti-PIM3 Recombinant Rabbit mAb; for WB/IHC/IF target validation; sequence verified. | View PIM3 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High Homology with PIM1/PIM2 (Selectivity) | Human PIM1/PIM2/PIM3 Kinase Panel with >95% purity, sequence verified for orthogonal cross-screening. |
| Drug Resistance Mutation Profiling | PIM3 Gatekeeper Mutants (T85M) available; strict mass spec verification; theoretical MW confirmed. |
| Cellular Target Engagement | Lentivirus for stable cell line construction (HEK293/oncogenic lines); enables phospho-substrate detection (CETSA, NanoBRET). |
| ATP-Competitive Binding Confirmation | Active kinase protein with verified ATP-site accessibility; endotoxin <1 EU/µg. |
| Lack of Control Reagents | Clinical benchmark antibodies and validated siRNA sets included for specificity checks and false-positive elimination. |
Live PIM3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PIM3 therapeutics is intensifying, with major players shifting focus from pan-PIM inhibitors to isoform-selective PIM3 targeting to mitigate compensatory redundancy from PIM1/PIM2. As first-generation pan-inhibitors (e.g., AZD1208) faced clinical challenges, the next wave of R&D is targeting PIM3-specific degradation (PROTACs) and combination therapies with PI3K/AKT inhibitors to overcome oncogenic bypass mechanisms in hepatocellular carcinoma and prostate cancer.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Pan-PIM Inhibitor (Small Molecule) | AstraZeneca, Genentech/Roche, Novartis, Eli Lilly, Incyte | Acute Myeloid Leukemia (AML), Hepatocellular Carcinoma, Prostate Cancer | Multi-kinase inhibition profiling (PIM1/2/3 triple panel) with high-purity proteins; selectivity screening |
| Isoform-Selective Inhibitor (Small Molecule) | Emerging Biotech | Solid Tumors (HCC, Prostate, Colorectal) | Kinase activity assay (active WT + mutant PIM3); selectivity panel (PIM1/2); mutant profiling |
| PROTAC/Degrader | Emerging Biotechs | Refractory Cancers | Target engagement assay (cellular); mutant degradation resistance profiling; NanoBRET/Western blot |